Endometrial cancer is the commonest gynecological cancer, the majority is endometrioid type, diagnosed at an early stage with 69-88% 5-year survival. Low-grade endometrial cancers have low recurrence rates and often do not receive adjuvant therapy; however, a subset of these patients will have poor outcomes and would benefit from adjuvant treatment has been challenging. We evaluate the circulating cell-free DNA (ccfDNA) in a patient with low-risk endometrial cancer in order to identify the presence of molecular markers associated with risk of recurrence. The evaluation of mutation profile was performed by next-generation sequencing (NGS) in primary tumor formalin-fixed paraffin-embedded (FFPE) tissue and in circulating tumor DNA (ctDNA). We identified a specific mutational profile in ctDNA, different from primary tumor tissue suggesting that the clone involved in the relapse may be different in comparison to the most represented in the primary tumor. These findings open new prospective and new wonderings. The molecular characterization of tissue may be useful for setting new target personalized therapy even in the treatment of endometrial cancer, moreover, endometrial cancer at low risk should be not underestimated for the incidence of relapse, and for this evaluation the molecular characterization may be useful. Moreover, these results suggest that the single analysis of primary tumors may be not sufficient for setting a specific personalized therapy targeted to avoid the relapse but may be necessary to join the molecular characterization of liquid biopsy to primary tissue. Anti-Cancer Drugs 31: 1091-1095.

Mutational profile in circulating tumor DNA in a patient affected by low-risk endometrial cancer: Predictable tool of relapse? / Malentacchia F.; Turrini I.; Zepponi F.; Fantappie G.; Sorbi F.; Antonuzzo L.; Fambrini M.; Noci I.; Pillozzi S.. - In: ANTI-CANCER DRUGS. - ISSN 0959-4973. - ELETTRONICO. - 31:(2020), pp. 1091-1095. [10.1097/CAD.0000000000000963]

Mutational profile in circulating tumor DNA in a patient affected by low-risk endometrial cancer: Predictable tool of relapse?

Turrini I.;Sorbi F.
Writing – Original Draft Preparation
;
Antonuzzo L.;Fambrini M.;Noci I.;Pillozzi S.
2020

Abstract

Endometrial cancer is the commonest gynecological cancer, the majority is endometrioid type, diagnosed at an early stage with 69-88% 5-year survival. Low-grade endometrial cancers have low recurrence rates and often do not receive adjuvant therapy; however, a subset of these patients will have poor outcomes and would benefit from adjuvant treatment has been challenging. We evaluate the circulating cell-free DNA (ccfDNA) in a patient with low-risk endometrial cancer in order to identify the presence of molecular markers associated with risk of recurrence. The evaluation of mutation profile was performed by next-generation sequencing (NGS) in primary tumor formalin-fixed paraffin-embedded (FFPE) tissue and in circulating tumor DNA (ctDNA). We identified a specific mutational profile in ctDNA, different from primary tumor tissue suggesting that the clone involved in the relapse may be different in comparison to the most represented in the primary tumor. These findings open new prospective and new wonderings. The molecular characterization of tissue may be useful for setting new target personalized therapy even in the treatment of endometrial cancer, moreover, endometrial cancer at low risk should be not underestimated for the incidence of relapse, and for this evaluation the molecular characterization may be useful. Moreover, these results suggest that the single analysis of primary tumors may be not sufficient for setting a specific personalized therapy targeted to avoid the relapse but may be necessary to join the molecular characterization of liquid biopsy to primary tissue. Anti-Cancer Drugs 31: 1091-1095.
2020
31
1091
1095
Goal 3: Good health and well-being for people
Malentacchia F.; Turrini I.; Zepponi F.; Fantappie G.; Sorbi F.; Antonuzzo L.; Fambrini M.; Noci I.; Pillozzi S.
File in questo prodotto:
File Dimensione Formato  
Mutational_profile_in_circulating_tumor_DNA_in_a.98542 (1).pdf

Accesso chiuso

Descrizione: Articolo principale
Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: DRM non definito
Dimensione 233.31 kB
Formato Adobe PDF
233.31 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1214675
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact